Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of atacicept in IgA nephropathy
2020-004892-41Phase 2Active
- Sponsor
- Vera Therapeutics
- Start
- May 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Atacicept arm with Placebo arm (2 arms). Primary endpoint: Urine protein to creatinine ratio (UPCR). Started May 2021; status: active.
02
Drugs
atacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2020-004892-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004892-41.